BRIEF-Roche Says Phase III Celestimo Study Meets Primary Endpoint In Follicular Lymphoma

2

Sept 17 (Reuters) – ROCHE HOLDING AG: * LUNSUMIO-BASED REGIMEN SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL IN FOLLICULAR LYMPHOMA IN PHASE III CELESTIMO STUDY * PHASE III CELESTIMO STUDY MEETS

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)